Shattuck Labs initiates Phase 2b RECEPTIVE-CD1 trial of SL-325 in Crohn's disease, with 12-week induction data expected in H1 2028

Shattuck Labs initiated the RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease, with 12-week induction data expected in H1 2028. The company expects to start a Phase 2 trial in hidradenitis suppurativa in Q4 2026.

Detected & updated continuously · Source: Nebula